Fast & Simple Syndromic Testing for Severe Infections
The Unyvero multiplex diagnostic panels are based on a molecular approach, using multiplex PCR technology to detect a broad range of clinically relevant microorganisms and antibiotic resistance markers to quickly and accurately identify infectious agents, from sample-to-answer in less than 5 hours.
Our syndromic approach is changing infectious disease diagnostics, providing rapid, comprehensive, and actionable results, directly from native specimen.
Faster and more sensitive than culture and traditional microbiological methods.
Traditional microbiology testing methods are slow and lack sensitivity. Consequently, patients are often initially treated with empiric broad-spectrum antibiotics without a laboratory result. Unyvero multiplex diagnostic panels offer fast and reliable pathogen identification and resistance marker detection, which can enable:
- Earlier targeted therapy
- Judicious use of antibiotics
- Reduction in unnecessary antibiotic treatment costs and associated side effects
- Reduction in spread and rise of antibiotic resistance
Antibiotic resistant microorganisms are a global health threat
Antimicrobial stewardship programs (ASP) promote appropriate use of antimicrobials in order to improve patient outcomes, reduce antimicrobial resistance, decrease the spread of infections caused by multidrug-resistant organisms (MDRO), and reduce hospital costs. Misuse and overuse of antimicrobials is one of the world’s most pressing public health problems. With antimicrobial resistance on the rise worldwide and few new agents in development, antimicrobial stewardship initiatives are more important than ever in ensuring the continued efficacy of available antimicrobials.
The Unyvero panels are designed to simultaneously detect a broad range of clinically relevant microorganisms and antibiotic resistance, in a single test, enabling to rapidly identify the common probable pathogens and achieve targeted antibiotic selection more quickly. Optimal antibiotic coverage can lead to:
- Targeted therapy without delay
- Faster time to antibiotic therapy
- Reduced antibiotic use
- Decreased rate of antimicrobial resistance
- Reduced inappropriate treatment modalities
Unyvero is a registered trademark of Curetis GmbH, Germany. Curetis GmbH is an OpGen Group company.